Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KK8123 in X-linked Hypophosphatemia
NCT06525636Phase 2Recruiting
- Sponsor
- Kyowa Kirin
- Start
- Oct 2024
- Primary completion
- May 2029
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of KK8123 in X-linked hypophosphatemia (XLH), sponsored by Kyowa Kirin. Started Oct 2024; status: recruiting.
02
Drugs
KK8123
03
Conditions
X-linked hypophosphatemia (XLH)
Beyond the preview
Go deeper on NCT06525636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525636.